Skip to main content
padlock icon - secure page this page is secure

Inhibition of Calcium Oxalate Nephrotoxicity with Cymbopogon Schoenanthus (Al-Ethkher)

Buy Article:

$68.00 + tax (Refund Policy)

We investigated the effects of Cymbopogon schoenanthus herb on experimental induced kidney stones in male Wistar albino rats. Oxalate nephrotoxicity was experimentally induced by 200 mg single dose of glycolic acid given orally (gavage). Rats were divided into three groups, glycolic acid, glycolic acid plus Cymbopogon schoenanthus, and control (D. water). Urine analysis of blood urea nitrogen (BUN), creatinine, and calcium revealed significant differences comparing to the control. In addition, significant pathological changes were found in the kidney revealed by histopathological studies. Daily oral treatment with Cymbopogon schoenanthus (1 ml of the extract) significantly corrected the incidence of nephrotoxicity, BUN, creatinine, and calcium level differences. Moreover, optimization studies showed highly potent diuretic activity of Cymbopogon schoenanthus. After three days of experiments, four rats treated with the glycolic acid only died. The rest of animal survived and looked healthy.





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Cymbopogon schoenanthus; calcium oxalate; kidney stone; nephrotoxicity

Document Type: Research Article

Publication date: December 1, 2007

More about this publication?
  • Drug Metabolism Letters publishes short papers on major advances in all areas of drug metabolism and disposition. The emphasis will be on publishing quality papers very rapidly. Letters will be processed rapidly by taking full advantage of the Internet technology for both the submission and review of manuscripts. The journal covers the following areas:

    In vitro systems including CYP-450; enzyme induction and inhibition; drug-drug interactions and enzyme kinetics; pharmacokinetics, toxicokinetics, species scaling and extrapolations; P-glycoprotein and transport carriers; target organ toxicity and interindividual variability; drug metabolism and disposition studies; extrahepatic metabolism; phase I and phase II metabolism; recent developments for the identification of drug metabolites, reactive intermediate and glutathione conjugates.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more